Purpose: Fetal growth is a complex process involving maternal, placental and fetal factors. The etiology of fetal growth retardation remains unknown in many cases. The aim of this study is to identify novel human mutations and genes related to Silver-Russell syndrome (SRS), a syndromic form of fetal growth retardation, usually caused by epigenetic downregulation of the potent fetal growth factor IGF2.
INTRODUCTION
Intrauterine growth retardation (IUGR) is a common condition arising from multiple origins (environmental, (epi)genetic, vascular, etc.). 1 A well-characterized syndromic form of IUGR is represented by Silver-Russell syndrome (SRS, OMIM 180860). SRS is a clinically and genetically heterogeneous imprinting disorder characterized by fetal and postnatal growth retardation, relative macrocephaly at birth, a prominent forehead, and additional features. 2 The syndrome remains a clinical diagnosis, defined by clinical scoring systems. [2] [3] [4] [5] [6] Insulin-like growth factor 2 (IGF2) is a growth factor strongly implicated in fetal growth and in the pathophysiology of SRS, as up to 50-60% of patients display hypomethylation of the imprinted 11p15.5 IGF2/H19 domain, which leads to the downregulation of IGF2 expression. 2, 7, 8 The second most common cause of SRS is maternal uniparental disomy of chromosome 7, accounting for about 10% of cases. 2 Other rare 11p15.5-related genetic defects, such as maternal duplications, maternal CDKN1C mutation, 9 and paternal IGF2 point mutation 10 have also been implicated in SRS. In about 30-40% of patients with a clinical diagnosis of SRS, the molecular etiology of this syndrome remains unknown, involving molecular mechanisms and genes other than those cited above. 6 Pleomorphic adenoma gene 1 (PLAG1), on human chromosome 8q12, was initially identified as an oncogene associated with certain types of cancer (e.g., pleomorphic adenomas, lipoblastoma, hepatoblastoma). [11] [12] [13] The tumorigenic capacity of PLAG1 results from its ability to bind the P3 promoter of IGF2, thereby increasing IGF2 expression in tumor cells. [13] [14] [15] [16] In addition to functioning as an oncogene, PLAG1 has been implicated in growth, as Plag1 knockout mice and paternal Igf2-deficient mice have remarkably similar phenotypes, characterized by intrauterine and postnatal growth retardation. 17 The DNA-binding protein high-mobility group AT-hook 2 (HMGA2), located on human chromosome 12q14, is a transcription factor that has been identified as an oncogene 1 Sorbonne Universités, UPMC Univ Paris 06, UMR_S 938, CDR Saint-Antoine, Paris, France; 2 Service d'Explorations Fonctionnelles Endocriniennes, AP-HP, Hôpital Trousseau, Paris, France; 3 Endocrine, Bone Diseases, and Genetics Unit, Children's Hospital, University Hospital Center, Toulouse, France; 4 and shown to be an upstream regulator of PLAG1 expression in several tumor cells and experimental models. 18 Hmga2deficient mice have a pygmy phenotype and fetal growth retardation. 19 A splicing mutation of HMGA2 was recently associated with SRS in a family but the contribution of this mutation to the phenotype was not clearly assessed. 20 Rearrangements of 8q12 and 12q14 chromosomal regions corresponding to the locations of PLAG1 and HMGA2, respectively, have been reported in patients with SRS and SRS-like conditions. 21 Finally, GWAS meta-analysis studies on humans have shown HMGA2 and PLAG1 variants to be strongly correlated with childhood/adult height, highlighting the role of these genes in the control of human growth. [22] [23] [24] [25] Together, these observations strongly suggest that HMGA2 and PLAG1 play a role in growth physiology mediated by IGF2, but direct evidence has been lacking.
Here we report new mutations in the HMGA2-PLAG1-IGF2 pathway resulting in lower levels of IGF2 expression in SRS patients. These findings highlight the role of HMGA2 and PLAG1 as upstream regulators of IGF2.
MATERIALS AND METHODS

Population studied
The familial case and the 192 patients included in this study were referred for IUGR and suspected Silver-Russell syndrome. Blood samples were collected during clinical visits.
Written informed consent for participation was received from all patients or parents, in accordance with national ethics rules (Assistance Publique-Hôpitaux de Paris authorization no. 681 for French patients and IRB I00000204 at the Mount Sinai School of Medicine, New York, for patients recruited in the United States). Written consent was also obtained to publish patient photos. Patients were either followed at Armand Trousseau Children's Hospital or referred by other clinical centers for molecular analysis of suspected SRS. A geneticist and/or a pediatric endocrinologist examined each patient and a detailed clinical form was completed. Patients who were negative for methylation defects within the imprinted domains controlling IGF2/H19, DLK1/GTL2, and MEST/ GRB10 assessed by allele-specific methylated multiplex realtime quantitative polymerase chain reaction, as previously described, 2 were retained for further molecular analysis.
Whole-exome sequencing and targeted HMGA2-PLAG1-IGF2 sequencing Library preparation, exome capture/gene enrichment, sequencing, and data analysis were performed by IntegraGen SA (Evry, France). The sequencing methods and bioinformatics analysis are described in detail in the Supplementary Methods online.
Sanger sequencing and short tandem repeat typing HMGA2, PLAG1, and IGF2 mutations identified with wholeexome sequencing and targeted sequencing were verified by standard methods of Sanger sequencing, using the ABI PRISM Big Dye Terminator v3.0 Cycle Sequencing Kit and an ABI 3100 Genetic Analyzer (Life Technologies, Courtaboeuf, France). The sequencing products were then analyzed with SeqScape v2.6 (Life Technologies). For de novo mutations, parental inheritance was verified using short tandem repeat typing on chromosome 14 (D14S65 and D14S292).
Cell cultures and transfections
Fibroblasts, Hep3B, and HEK293 cells were cultured under standard conditions in supplemented RPMI 1640 and MEM, respectively (Gibco, Cergy Pontoise, France), at 37°C. Gene silencing and overexpression assays were performed according to the manufacturer's protocols (Thermo Fisher, France). Details of the culture conditions, gene silencing, and overexpression assays as well as RNA extraction are provided in the Supplementary Methods.
Reverse transcription and real-time messenger RNA quantification
We generated complementary DNA from the messenger RNA of fibroblasts, Hep3B, and HEK293 cells, with the SuperScript II reverse transcription system (#18064-014 Invitrogen Thermo Fisher, France). Real-time PCR was performed on the complementary DNAs obtained, in an ABI-7900HT machine, and gene expression was quantified with the Power SYBR Green PCR Master Mix (Life Technologies). Details from the reverse transcription and real-time quantification analysis are provided in the Supplementary Methods.
Statistical analysis
We compared data for pairs of groups in Mann-Whitney (expression in fibroblasts) and unpaired t (silencing and overexpressing assays) tests. We considered P values of less than 0.05 to indicate statistical significance. The analyses were performed with GraphPad Prism version 6.00 (GraphPad Software, La Jolla, CA).
RESULTS
Heterozygous PLAG1 frameshift mutation SRS was diagnosed clinically using the Netchine-Harbison clinical scoring system (NH-CSS) 2,6 in patient II-2 from the affected family ( Figure 1) . Molecular analysis revealed a normal methylation on chromosomes 11, 7, and 14. Singlenucleotide polymorphism array excluded maternal uniparental disomies and chromosomal rearrangements. The proband's sister and mother had similar phenotypes consistent with dominant transmission of the disease. Wholeexome sequencing revealed a heterozygous deletion of a single nucleotide within exon 5 of the PLAG1 gene (NM_002655.2: c.439del) in the proband, her mother, and her sister, but not in the father. This deletion leads to a frameshift and production of a truncated, 227-amino acid peptide (NP_002646.2:p.Ser147Valfs*82). This variant was not reported in any polymorphism or the ExAC database. The 18 other variants listed in Supplementary Table 1 , which were found in the three affected family members, have no known effect on growth. 2   115  22  48  47  46  45  44  43  42  41  40  39  38  37  36  35  34  33  32  31  30  29  28  27  26  25  24  23  22 GH GH GH GH 21 20 19 Weight (Ib) Weight (kg)   18  17  16  15  14  13  12  11  10  9  8  7  6  5  4  3   48  47  46  45  44  43  42  41  40  39  38  37  36  35  34  33  32  31  30  29  28  27  26  25  24  23  22  21  20  19 Weight (Ib)   18  17  16  15  14  13  12  11  10  9  8  7  6  5  4  3   45  44  43  42  41  40   39  38  37  36  35  34  33  32  31  30  29  28  27  26  25  24  23  22 21 20 19 Length (in) Age (mo)   21 24 27 30 33 36   48  47  46  45  44  43  42  41  40  39  38  37  36  35  34  33  32  31  30  29  28  27  26  25  24  23  22  21  20  19 Weight (Ib)   18  17  16  15  14  13  12  11  10  9  8  7  6  5  4  3   45  44  43  42  41  40  39  38  37  36  35  34  33  32  31  30  29 48  47  46  45  44  43  42  41  40  39  38  37  36  35  34  33  32  31  30  29  28  27  26  25  24  23  22  21  20  19 Weight (Ib)   18  17  16  15  14  13  12  11  10  9  8  7  6 We have selected 192 patients for whom a diagnosis of SRS was suspected and for whom we could not identify any known epigenetic or genetic cause of SRS. All these patients were born small for gestational age (birth weight and/or birth length o-2 standard deviation score (SDS)) and without body asymmetry, which is in favor of a genetic rather than an epigenetic defect. Of these patients, 76 displayed head circumference sparing with relative macrocephaly at birth.
Identification of new genetic defects affecting the HMGA2-PLAG1-IGF2 pathway
As PLAG1 plays a key role in the HMGA2-PLAG1-IGF2 pathway, we screened for mutations using high-throughput targeted sequencing for these three genes in the cohort of patients described above. We identified another heterozygous, de novo deletion of a single nucleotide in PLAG1 (NM_002655.2:c.1363del), leading to a frameshift and the production of a truncated, 469-amino acid protein (NP_002646.2:pGln455Serfs*16). This deletion was not found in the parents, the twin brother, or the older brother of the patient (Figure 1) . Two new heterozygous variants were identified in the HMGA2 gene: a de novo nonsense mutation (NM_003483.4:c.193C > T) leading to premature termination (NP_003474.1:p.Gln65*), and a deletion of a single nucleotide (NM_003483.4:c.189del) leading to an elongated protein (NP_003474.1:p.Ala64Leufs*102) ( Table 1) . Due to lack of parental DNA, the origin of this deletion could not be investigated, but the father's adult height of 155 cm strongly suggests that he passed this deletion to his son. Finally, we found two heterozygous variations within the IGF2 gene: a de novo nonsense mutation (NM_000612.5: c.78C > G) leading to the production of a truncated peptide (NP_000603.1:p.Tyr26*), and a de novo two-nucleotide duplication (NM_000612.5:c.158_159dup) leading to a frameshift and the production of a truncated 59-amino acid protein (NP_000603.1:p.Arg54Alafs*7). All five mutations were identified in the group of 76 patients with relative macrocephaly at birth.
Clinical data
The clinical presentation of the patients harboring the mutations is summarized in Table 1 . We were unable to categorize patient I-2 due to a lack of information about some of her clinical signs. For the remaining patients, five out of seven fulfilled the SRS clinical diagnostic criteria of the NH-CSS (at least four of six criteria, including relative macrocephaly). Patient II-1 fulfilled only three of the six criteria from the NH-CSS and patient II-2 fulfilled four of six criteria without relative macrocephaly at birth. Birth weights and lengths were most strongly affected for patients with IGF2 and HMGA2 mutations (respectively), with a slightly smaller effect observed in patients with PLAG1 defects. Similarly, relative macrocephaly, defined as a difference in SDS of at least 1.5 between head circumference and length or weight at birth, was more pronounced in patients with the IGF2 mutations. As is characteristic of SRS, all patients presented with significant feeding difficulties and need for nutritional support with nonvolitional feeding and/or appetite stimulation. Serum IGF2 levels and other related markers from the patients with PLAG1, HMGA2, and IGF2 mutations are listed in Table 1 .
Regulation of IGF2 levels by HMGA2 and HMAG2-PLAG1 pathway
The small interfering RNA (siRNA)-mediated silencing of HMGA2 in Hep3b cells decreased PLAG1 and total IGF2 expression ( Figure 2a ). Silencing of PLAG1 resulted in lower levels of total IGF2, but did not change the levels of HMGA2 expression (Figure 2a ). Since PLAG1 binds specifically to the IGF2 promoter P3, we assessed the levels of IGF2 generated by transcription from the P1 and P3 promoters (IGF2-P1 and IGF2-P3, respectively). The silencing of both HMGA2 and PLAG1 led to a downregulation of IGF2-P3, whereas IGF2-P1 expression remained normal (Figure 2b) . Finally, H19 expression was not affected by the silencing of either HMGA2 or PLAG1. PLAG1 therefore acts as a trans-acting factor at the IGF2-P3 promoter, but does not affect the whole IGF2/H19 domain (Figure 2a ). IGF2-P3 levels were significantly lower in siHMGA2-treated than in siPLAG1-treated cells despite the production of significantly lower levels of PLAG1 in siPLAG1-treated cells (Figure 2a,b ), suggesting a PLAG1-independent HMGA2 regulation of IGF2. In order to verify this, we performed an overexpressing assay of HMGA2 and PLAG1 in HEK293 cells. Overexpression of HMGA2 in these cells resulted in an increased expression of IGF2-P3, without affecting the messenger RNA levels of PLAG1 (Figure 2c ). However, PLAG1 maintained its capacity to upregulate IGF2-P3 upon PLAG1 overexpression (Figure 2c) . These results show that HMGA2 and PLAG1 both positively regulate IGF2-P3 expression, independently or via a HMGA2-PLAG1-IGF2 pathway.
We further investigated gene expression in fibroblasts from patient I-2 from the family (Figure 1) carrying the PLAG1 deletion. The levels of PLAG1 expression were similar to those in controls, but IGF2 expression was half that of the controls (Figure 2d ).
DISCUSSION
IGF2 has been identified as a major factor in the control of fetal growth in many species, including humans. IGF2 is a maternally imprinted gene, and its expression is regulated mostly by epigenetic marks. 27 Epigenetic and genetic defects within 11p15.5 have been implicated in syndromes involving growth retardation (SRS, with IGF2 downregulation) 28 or overgrowth (Beckwith-Wiedemann syndrome, with IGF2 overexpression). 29 Furthermore, the overexpression of IGF2 is frequently observed in several types of tumors, including embryonal tumors in particular. 30 The epigenetic regulation of IGF2 expression is well described, but the upstream genetic mechanism by which IGF2 expression is regulated remains unknown. Head circumference at birth ≥ 1.5 SDS above birth weight and/or length SDS. b For this adult patient, the Netchine-Harbison clinical scoring system was determined from four criteria only, as the two additional items (birth head circumference and BMI at 2 years) were not available. c Cyproheptadine, a first-generation antihistamine, has also been used as an orexigenic drug in some pediatric disorders with malnutrition. 26 d IGF2 Mediagnost RIA assay, 3-7 years normal range 397-973 ng/ml. e IGF2 Esoterix assay, prepubertal normal range 334-642 ng/ml.
We report the first mutations of PLAG1 in a familial case with dominant transmission of syndromic IUGR associated with SRS and in another sporadic case of SRS with a de novo mutation. Since PLAG1 is a key factor in the HMGA2-PLAG1-IGF2 pathway, we screened for and identified mutations of the HMGA2 and IGF2 genes. These findings highlight the crucial role of this pathway in controlling fetal IGF2 levels and its involvement in the pathophysiology of IUGR and SRS (Figure 3) .
These observations also demonstrate that, in addition to epimutation at the 11p15 locus and mutation in the imprinted IGF2 gene, SRS may be caused by mutations of genes controlling IGF2 expression, such as PLAG1 and HMGA2. Though previously shown in mice, 31 this is one of the first examples in humans, where nonimprinted genes deregulate the expression of distant, normally imprinted genes.
The mutations we identified in PLAG1 and HMGA2 were heterozygous leading to dominant transmission of SRS. The mutations we found in IGF2 were also heterozygous, but because IGF2 is paternally expressed in most tissues during fetal and postnatal development, to induce the SRS phenotype, an IGF2 mutation must occur on the paternal allele. We could not find any other inherited polymorphism near the de novo mutations in the IGF2 gene to specifically determine the parental origins of these mutations. However, given the typical SRS phenotype of these reported patients who carry the de novo IGF2 mutations, it is very likely that the mutations affected their paternal alleles, consistent with the imprinted status of this gene.
Very few mechanistic data on the HMGA2-PLAG1-IGF2 pathway or its role in pathological processes have been reported to date. All previous studies have shown HMGA2-PLAG1 and PLAG1-IGF2 expression levels to be correlated, in overexpression models or in tumors. 18, 32 Murine models with inactivation of Hmga2, 19 Plag1, 17 or Igf2 33 display growth retardation, but the processes underlying the pathological phenotype have yet to be determined. We show that the disruption of any genes in this pathway leads to a decrease in IGF2 expression and produces a SRS phenotype, similar to patients carrying 11p15.5 epigenetic defects. We also show that this downregulation of IGF2 expression is caused by a lack of activation of the IGF2 P3 promoter, consistent with the results of previous studies showing a direct interaction between PLAG1 and this promoter. 34 IGF2-P3 is the main transcript and is highly active in fetal tissues, whereas IGF2-P1 is active only in the liver after birth. 35 This specific action at IGF2-P3 may account for the nondecreased levels of IGF2 in patients with mutations of the PLAG1 and HMGA2 genes. Indeed, circulating IGF2 is synthesized from the P1 promoter in a biallelic fashion by the adult liver in humans with no imprinting in this organ. 36 The silencing of HMGA2 or PLAG1 had no effect on IGF2 transcription from the P1 promoter. Therefore, patients with an HMGA2-PLAG1 defect display conserved P1 transcription activity in the liver, resulting in normal postnatal IGF2 serum levels. The patients with the IGF2 mutations had low normal or modestly decreased levels of IGF2 in the serum ( Table 1) . In this case, the circulating IGF2 was probably produced by transcription from the unaffected allele alone. This is in accordance with the modestly decreased circulating IGF2 levels observed in the previously described patients carrying paternal IGF2 10 mutations ( Table 1) .
As expected with a genetic defect, none of the cases have body asymmetry. In a family carrying this kind of mutation, body asymmetry is not expected to occur because the molecular defect is present in all the cells of the body (unlike the mosaic epigenetic change at the 11p15.5 locus). Thus, the absence of body asymmetry does not exclude the diagnosis of SRS in this particular case. However, despite the fact that patients harboring a genetic defect of the HMGA2-PLAG1-IGF2 pathway presented IUGR and an SRS clinical diagnosis, some differences were observed between the phenotypes. Indeed, patients with the IGF2 and HMGA2 defects were smaller at birth and their head circumferences were larger than those patients with PLAG1 defects. These differences between the phenotypes could simply reflect individual human variations, and more cases are needed to confirm these observations. Such variability is also observed within the group of SRS patients with IGF2/H19 hypomethylation. However, using siRNA-based silencing technique in cell lines, we showed that HMGA2 silencing led to significantly lower levels of IGF2 expression than PLAG1 silencing, despite a more effective PLAG1 downregulation in the latter silencing assay. Furthermore, using vector-based overexpressing technique in another cell line, we showed that HMGA2 is capable of regulating IGF2 expression in a PLAG1-independent manner. Thus, IGF2 expression is more strongly affected by IGF2 and HMGA2 mutations, respectively, than by PLAG1 mutations.
The elucidation of these new genetic mechanisms has major implications for genetic counseling. In keeping with the imprinted, paternally expressed nature of the gene, males carrying IGF2 mutations have a 50% risk of transmitting the disorder. As HMGA2 and PLAG1 are not imprinted, males and females with mutations of these genes both have a 50% risk of transmitting SRS. Given this high risk of SRS transmission, screening for mutations of these genes should be considered in cases of SRS presenting with no epigenetic defect of 11p15.5 or maternal disomy of chromosome 7. Furthermore, in the context of next-generation sequencing, these genes could be included in panels for the screening of growth retardation disorders for patients with no 11p15 epimutations or maternal disomy of chromosome 7 or 14.
In conclusion, we show for the first time that defects of the HMGA2-PLAG1-IGF2 pathway can lead to SRS, highlighting the role of this oncogenic pathway in the fine regulation of physiological fetal/postnatal growth and food intake. We also show that nonimprinted genes can deregulate the expression of distant imprinted genes in humans. Given the crucial role played by the low level of IGF2 expression in the outcome of IUGR and the SRS phenotype, identification of new targets of IGF2 will be the next step in the development of new treatment options for this group of patients.
Accession numbers
The ClinVar accession numbers for the PLAG1, HMGA2, and IGF2 variant sequences reported in this paper are listed in Table 1 . 
